| Symbol | IFRX |
|---|---|
| Name | INFLARX N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | WINZERLAER STRASSE 2, JENA, 7745, Germany |
| Telephone | +49 3641508180 |
| Fax | — |
| — | |
| Website | https://www.inflarx.de |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001708688 |
| Description | InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Additional info from NASDAQ: |
New Form 424B5 - InflaRx N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001140361-26-033149 <b>Size:</b> 1 MB
Read moreNew Form SCHEDULE 13G - InflaRx N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005206 <b>Size:</b> 14 KB
Read moreNew Form SCHEDULE 13G/A - InflaRx N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000908834-26-000421 <b>Size:</b> 45 KB
Read moreNew Form EFFECT - InflaRx N.V. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 9999999995-26-002649 <b>Size:</b> 1 KB
Read moreInflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Read moreInflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Read moreInflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Read moreInflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Read more